Clinical Trial Update: Virus-specific Activated T Lymphocytes From a Donor in Hematopoietic Progenitor Transplanted Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating donor-derived virus-specific activated T lymphocytes for CMV viremia in immunosuppressed hematopoietic progenitor transplant patients…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cmv Viremia
• Immunosuppression-related Infectious Disease

Drugs mentioned

• Virus-specific activated T lymphocytes (donor-derived)

Snippet

Sponsor: Banc de Sang i Teixits | Conditions: CMV Viremia, Immunosuppression-related Infectious Disease | Phase 1, Phase 2 | Status: COMPLETED